Veracyte, Inc. Files Definitive Proxy Statement

Ticker: VCYT · Form: DEF 14A · Filed: Apr 25, 2024 · CIK: 1384101

Veracyte, Inc. DEF 14A Filing Summary
FieldDetail
CompanyVeracyte, Inc. (VCYT)
Form TypeDEF 14A
Filed DateApr 25, 2024
Risk Levellow
Pages15
Reading Time19 min
Key Dollar Amounts$361.1 m, $296.5 million, $44.2 million, $216.5 million
Sentimentneutral

Sentiment: neutral

Topics: Veracyte, VCYT, DEF 14A, Proxy Statement, Executive Compensation

TL;DR

<b>Veracyte, Inc. has filed its Definitive Proxy Statement for the period ending June 12, 2024, detailing executive compensation and corporate governance matters.</b>

AI Summary

VERACYTE, INC. (VCYT) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Veracyte, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 25, 2024. The filing covers the period ending June 12, 2024. The company's principal executive offices are located at 6000 Shoreline Court, Suite 300, South San Francisco, CA 94080. Veracyte, Inc. was formerly known as Calderome Inc. until December 19, 2006. The filing includes information related to equity awards for the fiscal year ending December 31, 2023.

Why It Matters

For investors and stakeholders tracking VERACYTE, INC., this filing contains several important signals. This DEF 14A filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions on proposals presented at the upcoming shareholder meeting. The detailed information on equity awards and their valuation provides insight into how the company incentivizes its key personnel and aligns their interests with shareholders.

Risk Assessment

Risk Level: low — VERACYTE, INC. shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate governance and disclosure practices with no immediate red flags.

Analyst Insight

Shareholders should review the proxy statement to understand executive compensation and vote on relevant proposals.

Key Numbers

  • 2024-04-25 — Filing Date (Date the DEF 14A was filed)
  • 2024-06-12 — Report Period End Date (Conformed period of report)
  • 2023-12-31 — Fiscal Year End (Fiscal year end for compensation data)

Key Players & Entities

  • VERACYTE, INC. (company) — Registrant name
  • 6000 SHORELINE COURT, SUITE 300 (address) — Business address
  • SOUTH SAN FRANCISCO (location) — Business address city
  • CA (location) — Business address state
  • 94080 (postal_code) — Business address zip
  • CALDEROME INC (company) — Former company name

FAQ

When did VERACYTE, INC. file this DEF 14A?

VERACYTE, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 25, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by VERACYTE, INC. (VCYT).

Where can I read the original DEF 14A filing from VERACYTE, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by VERACYTE, INC..

What are the key takeaways from VERACYTE, INC.'s DEF 14A?

VERACYTE, INC. filed this DEF 14A on April 25, 2024. Key takeaways: Veracyte, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 25, 2024.. The filing covers the period ending June 12, 2024.. The company's principal executive offices are located at 6000 Shoreline Court, Suite 300, South San Francisco, CA 94080..

Is VERACYTE, INC. a risky investment based on this filing?

Based on this DEF 14A, VERACYTE, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating standard corporate governance and disclosure practices with no immediate red flags.

What should investors do after reading VERACYTE, INC.'s DEF 14A?

Shareholders should review the proxy statement to understand executive compensation and vote on relevant proposals. The overall sentiment from this filing is neutral.

How does VERACYTE, INC. compare to its industry peers?

Veracyte operates in the medical laboratories sector, providing diagnostic tests and services.

Are there regulatory concerns for VERACYTE, INC.?

As a publicly traded company, Veracyte is subject to SEC regulations requiring the filing of proxy statements for shareholder meetings.

Industry Context

Veracyte operates in the medical laboratories sector, providing diagnostic tests and services.

Regulatory Implications

As a publicly traded company, Veracyte is subject to SEC regulations requiring the filing of proxy statements for shareholder meetings.

What Investors Should Do

  1. Review the executive compensation details provided in the DEF 14A.
  2. Understand the proposals to be voted on at the shareholder meeting.
  3. Assess the company's corporate governance practices as outlined in the filing.

Key Dates

  • 2024-04-25: Filing of Definitive Proxy Statement (DEF 14A) — Provides updated information on corporate governance and executive compensation.
  • 2024-06-12: Report Period End Date — The period covered by the proxy statement.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document. No prior filing details are available in the provided text for comparison.

Filing Stats: 4,634 words · 19 min read · ~15 pages · Grade level 11.7 · Accepted 2024-04-25 16:34:30

Key Financial Figures

  • $361.1 m — PMENTS Delivered total 2023 revenue of $361.1 million, an increase of 22% compared to $
  • $296.5 million — million, an increase of 22% compared to $296.5 million in 2022. Grew total test volume to 126
  • $44.2 million — compared to the prior year. Generated $44.2 million in cash from operating activities for t
  • $216.5 million — year with cash and cash equivalents of $216.5 million. Further strengthened the body of evid

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31 EXECUTIVE OFFICERS 34

EXECUTIVE COMPENSATION 35

EXECUTIVE COMPENSATION 35 EQUITY COMPENSATION PLAN INFORMATION 58 REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS 58 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 58 ADDITIONAL INFORMATION 59 OTHER MATTERS AND AVAILABLE INFORMATION 60 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this proxy statement, the words "expects," "anticipates," "intends," "estimates," "plans," "believes," "continuing," "ongoing," and similar expressions are intended to identify forward-looking statements. These are statements that relate to future events and include but not limited to, forward-looking statements that involve risks and uncertainties; our ability to execute our short-term and long-term growth strategies; our plans for environmental, corporate governance and social responsibility, and other future events. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors, including, but not limited to, the risks and uncertainties listed in our Annual Report on Form 10-K, filed on February 29, 2024, for the year ended December 31, 2023 and other reports filed with the U.S. Securities and Exchange Commission to which your attention is directed. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances. 1 PROXY STATEMENT SUMMARY This summary highlights information contained elsewhere in this proxy statement. You should read the entire proxy statement before voting. 2023 FINANCIAL AND BUSINESS HIGHLIGHTS AND RECENT COMPANY DEVELOPMENTS Delivered total 2023 revenue of $361.1 million, an increase of 22% compared to $296.5 million in 2022. Grew total test volume to

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.